Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients

Heloisa Helena de Sousa Marques[1],[2], Maria Aparecida Shikanai-Yasuda[2],[3], Luiz Sérgio Fonseca de Azevedo[2],[4], Hélio Helh Caiaffa-Filho[2],[5], Lígia Camera Pierrotti[2],[6], Maria Zilda de Aquino[1],[2], Marta Heloisa Lopes[2],[3], Natalya Zaidan Maluf[2],[7], Silvia Vidal Campos[2],[8] and Silvia Figueiredo Costa[2],[3]

[1]. Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [2]. Comissão de Infecção em Imunodeprimidos, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [3]. Departamento de Moléstias Infecciosas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [4]. Serviço de Transplante Renal, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [5]. Serviço de Biologia Molecular, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [6]. Divisão de Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [7]. Serviço de Microbiologia e Imunologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP. [8]. Serviço de Transplante de Pulmão, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP.

ABSTRACT

Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) is one of the most serious complications associated with solid organ and hematopoietic stem cell transplantation. PTLD is most frequently seen with primary EBV infection post-transplant, a common scenario for pediatric solid organ recipients. Risk factors for infection or reactivation of EBV following solid organ transplant are stronger immunosuppressive therapy regimens, and being seronegative for receptor. For hematopoietic stem cell transplantation, the risk factors relate to the type of transplant, human leukocyte antigen disparity, the use of stronger immunosuppressants, T-cell depletion, and severe graft-versus-host disease. Mortality is high, and most frequent in patients who develop PTLD in the first six months post-transplant. The primary goal of this article is to provide an overview of the clinical manifestations, diagnosis, accepted therapies, and management of EBV infection in transplant recipients, and to suggest that the adoption of monitoring protocols could contribute to a reduction in related complications.

Keywords: Epstein-Barr virus. Lymphoproliferative disorders. Transplantation. Diagnosis. Combined modality therapy.
treatment, mainly through the administration of antithymocyte globulin (ATG) or muromonab-CD3 (Orthoclone OKT3).

For patients undergoing hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy can lead to a mono- or polyclonal proliferation of B-cells infected with EBV, resulting in the development of PTLD. The highest incidence of disease is in the first five months post-transplant, with reported levels ranging from 0.5 to 22% based on different studies. Additional risk factors that are also significant are the use of unrelated donor material and graft-versus-host disease (GVHD)9-11.

CLINICAL SPECTRUM

There are no pathognomonic signs for PTLD; thus, it is essential to maintain a high degree of clinical suspicion and surveillance in order to make an early diagnosis. EBV infection and/or PTLD should be considered if the following signs or symptoms are present: I) a persistent fever, alone, or in association with gastrointestinal manifestations (diarrhea, abdominal pain, intestinal bleeding, protein-losing enteropathy, and, more rarely, intestinal perforation/obstruction); II) lymphadenopathy; III) tonsillar or adenoidal hypertrophy; IV) mononucleosis-like syndrome; V) hepatomegaly or splenomegaly; VI) anemia, leukopenia, pancytopenia, or hemophagocytosis; VII) graft dysfunction; or VIII) other pulmonary or central nervous system-associated signs or symptoms5,12.

DIAGNOSIS OF EBV-RELATED PTLD IN TRANSPLANT RECIPIENTS

A number of analyses are recommended for effective diagnosis and monitoring of EBV infection. Virus capsid antigen immunoglobulin (IgG and IgM (anti-VCA), and Epstein Barr nuclear antigen (EBNA) serology of the transplant recipient are recommended pre-transplant to determine if they may be susceptible to primary infection, reactivation, or carry a latent infection9. In addition, polymerase chain reaction (PCR) monitoring of viral replication should be conducted immediately post-transplant and periodically throughout the following year, depending on the risk status of the case13,14. There is evidence to support the efficacy of systematic PCR evaluation of EBV viral load in high-risk patients15.

Patients showing persistent viral replication, or those with initially high EBV levels, have a higher risk of progressing to PTLD. However, there are no precise protocols to determine the frequency of follow-up. Measurement of EBV load at the time of transplant, monthly for the first six months, and then every two months for the following six months has been suggested. In addition, weekly viral load measurements are recommended for the first six months for high-risk HSCT patients. Patients with two or more of the following risk factors are considered high-risk: susceptible, having an unrelated donor or human leukocyte antigens (HLA) disparity, or undergoing haploidentical transplantation, ATG therapy, or T-cell depletion6,11.

It is also important to mention that international standards have yet to be defined for EBV viral load measurement, this will be necessary to enhance inter-laboratory reliability9.

The term PTLD represents a spectrum of lymphoproliferative states that include benign conditions such as lymphoid hyperplasia, infectious mononucleosis-like disease, and malignancies, however, when not specified, PTLD generally refers to the neoplastic end of this spectrum. Neoplasia is defined as any two of the following three characteristics: I) destruction of the underlying lymph node architecture; II) monoclonality; and III) evidence of EBV infection in neoplastic cells15.

If PTLD is suspected a biopsy of the affected organ is recommended, with diagnosis based on World Health Organization (WHO) criteria. WHO PTLD classification includes four categories: I) early lesions; II) polymorphic PTLD; III) monomorphic PTLD, and IV) classical Hodgkin lymphoma-type PTLD16,17. Early lesions are characterized by a polyclonal lymphoid proliferation with B-, T- and plasma cells with phenotypic homogeneity. In polymorphic PTLD, lymphoid cells form destructive extranodal masses, tissue architecture is damaged, and there is a proliferation of monoclonal B-cells. Monomorphic PTLD often presents with RAS, Myc, and P53 mutations and, in some cases, an altered B-cell immunophenotype with low or minimal CD20 expression17-19.

Other examinations conducted to determine the extent of disease include bone marrow biopsy, lumbar puncture for cerebrospinal fluid (CSF) collection, and analysis besides radiological assessment. Chest and abdomen tomography and central nervous system (CNS) magnetic nuclear resonance can contribute to the diagnosis of PTLD in organs or systems located in the corresponding areas20, and, if a patient cannot receive a contrast for investigation of disease in the abdomen, magnetic nuclear resonance is a good alternative. Endoscopy and colonoscopy should be performed in patients with unexplained abdominal complaints and diarrhea following the exclusion of infection with other pathogens.

PREVENTION OF PTLD

Strategies for the prevention of EBV-related PTLD under investigation include immunoprophylaxis, chemoprophylaxis, and preemptive therapy. PCR analysis of peripheral blood for EBV viral load has been proven to be effective for early diagnosis of EBV-related PTLD, particularly for high-risk patients5. The detection of EBV DNA through quantitative real-time PCR (RTq-PCR) is currently considered the gold standard21. The adoption of monitoring protocols by different services has reduced the incidence of this complication, as observed by Imadome K and others; it has also improved overall PTLD-related survival and reduced morbidity for both solid organ transplantation and HSCT5,22,23. The monitoring of EBV viral load could indicate when immunosuppressive therapy should be reduced and/or antiviral agents administered. However, further research is required in order to develop individualized monitoring programs specific to transplant type and risk level24.

TREATMENT OF PTLD

There is no consensus on PTLD treatment; however, the main therapeutic options are as follows:

- A reduction in immunosuppressive therapy should be considered as the first-line of treatment, and must be individualized to each patient. With this strategy response
PTLD is an important area for further investigation. Although they are widely used, antiviral agents such as acyclovir and ganciclovir, alone, or in combination with immunoglobulins, have not been proven efficacious in the treatment of EBV-related PTLD.

- Anti-B-cell and anti-CD20 (Rituximab) specific chimeric monoclonal antibody treatment has shown promising results. Some have suggested that these be administered following reduction of immunosuppressive therapy. Descriptive studies have shown that early anti-CD20 treatment during HSCT conditioning in patients with B-cell lymphoma and severe aplastic anemia can prevent EBV reactivation with a low impact on immune reconstitution. In another study, a single dose of anti-CD20 (150mg/m²) was prescribed to 29 multi-visceral transplant recipients treated with ATG resulting in no cases of PTLD 6 months post-transplantation.

- Rituximab at a dose of 375mg/m² weekly for four weeks is also recommended. However, IgG levels should be monitored at monthly intervals since hypogammaglobulinemia is an adverse event related to its use. In such cases, it can be replaced with intravenous Ig (IVIG) below 500mg/dL.

- In patients with persistent or progressive disease, in spite of a reduction in immunosuppressive therapy, and evidence of graft rejection, or patients with an adverse reaction to Rituximab, treatment with low doses of cyclophosphamide and corticosteroids is indicated. This treatment should be guided by an onco-hematology group, which should be involved since clinical suspicion for diagnostic orientation, management definition and the follow-up of patients with PTLD.

- Radiotherapy or surgical resection are usually indicated in cases of localized disease and should be considered for patients with CNS PTLD.

- Selective restoration of impaired immune function through the adoptive transfer of EBV-specific cytotoxic T-cells has recently been used as pre-emptive treatment for EBV-related PTLD in HSCT patients. Donor-derived T-cells are stimulated, expanded over 3 to 4 weeks, and transferred to patients. EBV-related PTLD after haploidentical HSCT has been successfully treated using this method using cells from the haploidentical donor. In addition, a bank of EBV-cytotoxic T-cells from healthy donors has been used as an alternative source for allogeneic cord blood HSCT patients with adverse reactions to rituximab, for whom donors are not usually available.

In conclusion, PTLD is one of the most severe complications associated with organ transplantation. Early diagnosis requires a high level of clinical suspicion and vigilance. Patient outcomes can be improved through EBV viral load surveillance and the adoption of adequate preventive and therapeutic strategies. The optimization of monitoring, prevention, and treatment of EBV-PTLD is an important area for further investigation.

**CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

**REFERENCES**


